females. An altered lipid profile was observed during therapy with L-asparaginase especially (CH,TG), the means (222.3±62.9 mg/dl, 223.1±88.31 mg/dl) respectively were higher than the level before the initiation of therapy (158±36 mg/dl, 119.4±57.3mg/dl) and after induction (139.8±61.5 mg/dl, 96.2±30.7 mg/dl) and these were statistically highly significant (P-value <0.001) while no significant changes regarding other types of lipid profile. This study showed no significant changes of lipid profiles in relation to morphological type, risk of leukemia, sex, age and body mass index (BMI), before, during and after therapy with L-Asparaginase. Conclusion: Hyperlipidemia especially cholesterol and triglyceride levels were significantly higher during treatment with L -Asparaginse and were reversible after drug discontinuation but showed no significant correlation with age, BMI, risk group and morphological types.
INTRODUCTION
bnormal blood lipid levels have been associated with various forms of cancer including acute lymphoblastic leukemia (ALL), but a consistent profile has not emerged. [1] [2] [3] Asparaginase is a bacterial enzyme, which is an effective drug in childhood acute lymphoblastic leukemia protocols and it is used during the induction and intensification phase, it depletes the blood pool of asparagines, nonessential amino acid. Malignant lymphoid cells, in contrast to most of the healthy tissue cells, are unable to synthesize asparagine when there is no nutritional supply of this amino acid so that the depletion of the systemic pool of asparagine will lead to malignant cell death. [4] The native (unmodified) forms of Lasparaginase are derived from U EscherichiaU U coliU or Erwinia carotovora and are administered intravenously or intramuscularly. The intramuscular route is more commonly used in children because of lower risk of severe allergic reaction. Conjugation of polyethylene glycol to E-coli asparaginase (PEG-asparaginase) lowers the immunogenicity of this foreign protein and prolongs the drugs half-life, allowing for less frequent administration. [5] Although Lasparaginase is an effective anti-leukemia agent, it is also associated with side effects occurring either in a dose or time dependent fashion or as hypersensitivity reactions. [6] The most frequently encountered toxicities in Lasparaginase containing regimens are allergy (20%), thromboembolic events (2-11%), severe pancreatitis, hyperglycemia, and encephalopatly. [7, 8] A possible adverse reaction is an elevation in plasma triglyceride (TG) concentration which is reported to occur in up to 10% of treated children treated. [9] The A mechanism responsible for the hypertriglyceridemia is unknown, but a relationship with lipoprotein lipase (LPL) has been suggested which is an endothelial-bound enzyme responsible for triglyceride hydrolysis of circulating TG-rich lipoproteins, it is the ratelimiting enzyme for the removal of TG from circulation. [10] So the fasting plasma concentration of TG correlates with the activity of LPL [10, 11] , and L-asparaginase therapy may reduce synthesis of lipolytic enzymes (such as hepatic triglyceride lipase). [12] This study was carried out to determine whether there are abnormal blood lipid profiles that are specific for acute lymphoblastic leukemia and its treatment especially L-Asparaginase and its relations to age, sex, risk group and morphological types. together with L-Asparaginase (derived from U EscherichiaU U coliU ). Doxorubicin was also added to the treatment for high risk patients. Blood samples were obtained after an overnight fast for children whose ages were more than two years and 2-4 hours for children less than two years. The determination of serum lipids was done before, during induction of remission (where L-Asparaginase treatment was given for 3 or 4 consecutive days with a one week interval) and two weeks after completion of Lasparaginase therapy. Blood specimens were collected for lipid testing and were analyzed on the same day. Serum cholesterol (CH) and triglycerides (TG) were measured enzymatically on the Johnson and Johnson, warren, NJ. Serum high density lipoprotein cholesterol (HDL-C) was measured enzymatically on the same instrument, very low density and low density lipoproteins (VLDL and LDL) using dextran sulfate and magnesium sulfate as the precipitin reagent. LDL was calculated from these values using the formula of Friedewald et al. [13] Results were categorized according to hospital laboratory norms. Normal triglyceride was defined as a serum concentration of less than 110 mg/dl. [14] Cholesterol levels were categorized as desired less than 170 mg/dl, border line 170-199; and high ≥200. [15] Lipid profiles were correlated with age, sex, BMI, risk groups, and morphological subtypes of leukemia before, during and after Lasparaginase therapy. Statistical analysis was done to find the p. value using SPSS version 15, student's t test and pearson correlation were performed to determine differences between groups at diagnosis, during and after treatment. A value of P<0.05 was considered to be significant.
PATIENTS AND METHODS

RESULTS
The age and sex distribution of studied cases hyperlipidemia is presented in (Table-1) . Twenty were males and the rest were females. More than half of children aged 1-5 year. Table ( 3) Shows correlation between age and lipid profile before, during and after treatment. There was found no significant correlation between hyperlipidema before, during and after therapy with L-asparginase and the ages of patients. (Table-5 ), Shows the relation between lipid profile and patient's sex before, during and after treatment. There was no significant relation between sex and lipid profile. (Table-6 ), shows the correlation between lipid profile and BMI before, during and after treatment. There was no significant correlation between BMI and lipid profile. (Table-7) , Shows no significant relation between morphological types of acute lymphoblastic leukemia (L1,L2) and lipid profile before, during and after therapy. 
DISCUSSION
Lipid abnormalities have been described in children with Acute lymphoblastic leukemia (ALL) who have been treated with Lasparginase. In the current study hyperlipidemia was estimated to be 65.2% of patients with ALL during asparginase containing regimen. Similar results were observed by Ridola, et al, [16] while Parsons Sk [17] noticed hyperlipidemia only in 19% of patients with leukemia. The pathogentic mechanism of hyperlipidemia seems to be due to an increase in endogenous synthesis of VLDL and to a decreased lipoprotein Lipase activity with consequent decreased removal of triglycerides from plasma. [18] In this prospective study the mean serum cholesterol was significantly higher during therapy with Lasparginase as compared with the levels before therapy, similar results were observed by Naik et al [19] . This study also showed a significantly increased levels in TG, during therapy with L. asparaginase which was in agreement with finding of Mousolino et al [20] and Florenza, et al. [21] The explanation of low cholesterol levels before therapy is due to increase cholesterol synthesis and accumulation of cholesterol esters in tumor tissues and due to increase catabolism after therapy so it is considered as possible prognostic factor in malignancies as suggested in some studies. [22, 23] The present results prompted the hypothesis that the hypertriglyceridemia is induced by a suppression of lipoprotein lipase activity as a result of an increase in the apoCIII/apoCII ratio since apoCII is an important co-factor for lipoprprotein lipase and an excess amount of apoCIII inhibits its activity. [24, 25] Another study was done by Halton et al, [26] showed extremely elevated TG levels during combination therapy with L-asparaginase and corticosteroid, as corticosteroids and L-asparaginase are active antineoplastic agents most commonly used together in the remission induction phase of ALL that were not observed during therapy with steroid without L-asparaginase in children with solid tumors as there was no role of Lasparagiase in their protocol of therapy and suggested that L-asparaginase lead to specific alterations and may provide insight into the toxicity associated with the drug. Among the numerous effects of steroids is their influence on lipid metabolism, yet no consistent changes in plasma lipid have been reported after induction, the L-asparginase was discontinued and lipid profile was performed with rapid resolution of hyperlipidemia and there was no recurrence with next pulse of steroid treatment. [26] In the present study, plasma LDL was siginficantly increased during therapy similar result was observed by Patel MM, et al [27] and the explanation of this, that these individuals have deficient or defective LDL receptors so they remove plasma LDL at much lower rate and have considerably elevated levels. [28] On contrary ,in another study by parsons et al [17] observed a decrease in the ratio of LDL to apoB (which may indicate a shift to smaller, denser LDL particles) during treatment with Lasparaginase that reversed during maintenance therapy without L-asparaginase. This study showed no significant change of lipid profiles in relation to morphological type, risk of leukemia, sex, age and BMI before, during and after therapy with L-asparaginase, similar results were observed by other studies. [1, 29, 30] In conclusions, hperlipidemia due to Lasparaginase is reversible after drug discontinuation and is rarely associated with severe complications therefore antileukemic treatment should not be modified because of hyperlipidemia
